Ismn Stada

Isosorbide-5-Mononitrate, the active ingredient in Ismn, is a nitrate vasodilator presented as an oral tablet for oral use. It is employed to manage chronic stable angina by improving myocardial oxygen balance in adult patients. The drug releases nitric oxide, causing peripheral venous dilation, which reduces cardiac preload and afterload, thereby decreasing myocardial oxygen demand.

GNH USA supplies Ismn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets.

Ismn, a nitrate vasodilator, is used in the management of coronary artery disease‑related angina.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Effort‑induced angina: decreases chest pain during physical activity. - Ischemic heart disease: helps alleviate myocardial ischemia‑related discomfort.

Ismn may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache - Dizziness - Flushing - Hypotension - Nausea - Palpitations

Serious or Rare Side Effects: - Severe hypotension - Syncope - Myocardial infarction - Life‑threatening arrhythmias - Methemoglobinemia - Anaphylactic or severe allergic reactions

When prescribing Ismn, clinicians should consider specific safety measures.

- Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Concomitant nitrate use: avoid combining with other nitrate preparations to prevent excessive hypotension. - Phosphodiesterase‑5 inhibitors: do not use with sildenafil, tadalafil, or vardenafil due to risk of severe hypotension. - Hepatic or renal impairment: adjust therapy cautiously and monitor for accumulation. - Pregnancy and lactation: use only if clearly needed; safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Ismn can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Other nitrate preparations (e.g., nitroglycerin) – risk of profound hypotension. - Phosphodiesterase‑5 inhibitors (sildenafil, tadalafil, vardenafil) – may cause severe blood pressure drops. - Potent antihypertensives (e.g., intravenous nitroprusside) – additive hypotensive effect.

Moderate Interactions (Monitor Closely): - Diuretics – may enhance blood pressure‑lowering effect. - Beta‑blockers – combined effect on heart rate and blood pressure. - Calcium channel blockers – possible additive vasodilation. - Antiplatelet agents – monitor for increased bleeding risk. - CYP3A4 inhibitors – may increase plasma levels of isosorbide‑5‑mononitrate.